Figure 6
From: Socioeconomic disparities and the genomic landscape of gastric cancer
Distribution of therapies with clinical benefit between LSES and MHSES groups. Overall, LSES patients had a higher potential inclusion rate in clinical trials than MHSES patients (73.0% vs. 67.0%). Accordingly, the percentage of patients who would qualify for drug treatment with clinical relevance in other tumor types was higher in the LSES group than in the MHSES group (53% vs. 33%).
